Literature DB >> 1652589

Establishment of a variety of human bone marrow stromal cell lines by the recombinant SV40-adenovirus vector.

S Aizawa1, M Yaguchi, M Nakano, S Inokuchi, H Handa, K Toyama.   

Abstract

Various human bone marrow stromal cell lines were established from the adherent cell populations by introduction of the recombinant SV40-adenovirus vector with an infection or electric poration procedure. As compared with DNA transfection, the vector introduction was able to immortalize the cells with more than 100 times higher efficiency. Morphological and cytochemical analyses indicated that various cloned cell lines with different properties were isolated by the vector introduction. All the established cell lines expressed SV40 large T antigen. These results provided the evidence indicating that the recombinant SV40-adenovirus vector was a useful tool to establish a variety of cell lines with different biological activities from human bone marrow stroma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1652589     DOI: 10.1002/jcp.1041480209

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  3 in total

1.  Transfer of SV40 temperature-sensitive early gene into human epidermal keratinocytes by the recombinant adenovirus vector.

Authors:  M Takayama; E Kim; M Kidokoro; K Shimamura; K Shiroki; H Yajima; A Kosukegaw; H Handa; A S Inokuchi
Journal:  In Vitro Cell Dev Biol Anim       Date:  2000-02       Impact factor: 2.416

2.  Immortalization of human epidermal keratinocytes by the recombinant SV40 adenovirus vector.

Authors:  S Inokuchi; K Hashimoto; T Mitomi; M Ueda; H Handa
Journal:  In Vitro Cell Dev Biol       Date:  1991-11

3.  Stromal cells in bone marrow play important roles in pro-inflammatory cytokine secretion causing fever following bortezomib administration in patients with multiple myeloma.

Authors:  Dai Maruyama; Takashi Watanabe; Yuji Heike; Kumiko Nagase; Noriko Takahashi; Satoshi Yamasaki; Fusako Waki; Hiroki Yokoyama; Sung-Won Kim; Yukio Kobayashi; Shin Aizawa; Kensei Tobinai
Journal:  Int J Hematol       Date:  2008-11-07       Impact factor: 2.490

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.